Search stocks

Find any stock by ticker or company name

Home

MIST

Milestone Pharmaceuticals Inc. (MIST)

NMS – Real Time Price. Currency in USD

1.17

-0.10 (-7.48%)

Market open: Aug 12, 2026, 11:18 AM EDT

1.26

-0.01 (-0.80%)

Previous after-hours: Aug 11, 2026, 7:56 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Instagram
Telegram
LinkedIn

Home
Watchlist
Markets
Calendar
Screener
News
About

MIST - Milestone Pharmaceuticals Inc. Latest News | Finranks

Home

MIST

Milestone Pharmaceuticals Inc. (MIST)

NMS – Real Time Price. Currency in USD

1.17

-0.10 (-7.48%)

Market open: Aug 12, 2026, 11:18 AM EDT

1.26

-0.01 (-0.80%)

Previous after-hours: Aug 11, 2026, 7:56 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

12.08.2026

Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates

Milestone Pharmaceuticals (MIST) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.2 per share a year ago.

12.08.2026

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage for CARDAMYST® (etripamil) nasal spray

04.08.2026

Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026

MONTREAL and CHARLOTTE, N.C., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report financial results for the second quarter ended June 30, 2026, on Wednesday, August 12, and provide a business update before the market open.

Videos

No Data

There is no data to display

Press releases

12.08.2026

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage for CARDAMYST® (etripamil) nasal spray

Search stocks

Milestone Pharmaceuticals Inc. (MIST)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Milestone Pharmaceuticals Inc. (MIST)

Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026

Videos

No Data

Press releases

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update